Medical Oncology

, 31:26 | Cite as

Expression and correlation of matrix metalloproteinase-9 and heparanase in patients with breast cancer

  • Dabei Tang
  • Ying Piao
  • Shu Zhao
  • Xudong Mu
  • Shuo Li
  • Wenjie Ma
  • Ying Song
  • Jingxuan Wang
  • Wenhui ZhaoEmail author
  • Qingyuan ZhangEmail author
Original Paper


Matrix metalloproteinase-9 (MMP-9) and heparanase (HPSE) are thought to be involved in tumor progression and metastasis. However, up to now, there are no studies that simultaneously investigated the expression levels of MMP-9 and HPSE in tumor tissue and serum of breast cancer patients. Their correlation in breast cancer pathological processes is unknown. The purpose of this study was to investigate the expression profile of MMP-9 and HPSE in breast cancer and to assess their clinicopathological significance. We measured serum MMP-9 and HPSE by enzyme-linked immunosorbent assay in healthy women, and in patients with benign and malignant breast disease. We also evaluated the expression of MMP-9 and HPSE protein in paraffin-embedded tumor tissues by immunohistochemistry. We then correlated serum and tissue levels of MMP-9 and HPSE in breast cancer samples and their expression with patients’ clinicopathologic characteristics. We found that serum levels of MMP-9 and HPSE were significantly higher in breast cancer patients than in benign breast disease and in healthy controls (P = 0.001). There was positive correlation between MMP-9 and HPSE in breast cancer patients. The tissue and serum levels of MMP-9 were associated with histology grade, lymph node status, pathological stage, and lymphovascular invasion (all P < 0.05). The tissue levels of MMP-9 were also associated with ER (P = 0.038) and Ki-67 (P = 0.032). The tissue and serum levels of HPSE expression were associated with tumor size, histology grade, lymph node status, and pathological stage (all P < 0.05). Our findings suggested that MMP-9 and HPSE might further be evaluated as biomarkers for predicting progression and prognosis of breast cancer.


MMP-9 Heparanase Breast cancer Serum biomarker Tumor prognosis Metastasis 



The study was supported by the foundation of science and technology research project of Heilongjiang education department.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Veronesi U, Marubini E, Del Vecchio M, et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst. 1995;87:19–27.PubMedCrossRefGoogle Scholar
  3. 3.
    Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284:67–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Reiland J, Sanderson RD, Waguespack M, et al. Heparanase degrades syndecan-1 and perlecan heparan sulfate functional implications for tumor cell invasion. J Biol Chem. 2004;279:8047–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Gomes AM, Stelling MP, Pavão MSG. Heparan sulfate and heparanase as modulators of breast cancer progression. BioMed Res Int. 2013;2013:852093.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Cupić DF, Tesar EC, Ilijas KM, et al. Expression of matrix metalloproteinase 9 in primary and recurrent breast carcinomas. Coll Antropol. 2011;35:7–10.PubMedGoogle Scholar
  7. 7.
    Wu ZS, Wu Q, Yang JH, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008;122:2050–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol. 1999;189:161–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Nanda DP, Sil H, Moulik S, et al. Matrix metalloproteinase-9 as a potential tumor marker in breast cancer. J Environ Pathol Toxicol Oncol. 2013;32:115–29.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhao M, Hu HG, Huang J, et al. Expression and correlation of Twist and gelatinases in breast cancer. Exp Ther Med. 2013;6:97–100.PubMedCentralPubMedGoogle Scholar
  11. 11.
    Maxhimer JB, Quiros RM, Stewart R, et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery. 2002;132:326–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Tang D, Zhang Q, Zhao S, et al. The expression and clinical significance of microRNA-1258 and heparanase in human breast cancer. Clin Biochem. 2013;46:926–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhao S, Ma W, Zhang M, et al. High expression of CD147 and MMP-9 is correlated with poor prognosis of triple-negative breast cancer (TNBC) patients. Med Oncol. 2013;30:335.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Sung H, Choi JY, Lee SA, et al. The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer. BMC Cancer. 2012;12:193.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem. 2011;44:869–72.PubMedCrossRefGoogle Scholar
  16. 16.
    La Rocca G, Pucci-Minafra I, Marrazzo A, et al. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer. 2004;90:1414–21.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Zhang W, Yang HC, Wang Q, et al. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res. 2011;31:3423–8.PubMedGoogle Scholar
  18. 18.
    Rao JS, Gondi C, Chetty C, et al. Inhibition of invasion, angiogenesis, tumor growth, and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non–small cell lung cancer cells. Mol Cancer Ther. 2005;4:1399–408.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Cassinelli G, Lanzi C, Tortoreto M, et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol. 2013;85:1424–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Chen Y, Chen Y, Huang L, et al. Evaluation of heparanase and matrix metalloproteinase-9 in patients with cutaneous malignant melanoma. J Dermatol. 2012;39:339–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Raghu H, Sodadasu PK, Malla RR, et al. Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer. 2010;10:647.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Fux L, Feibish N, Cohen-Kaplan V, et al. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 2009;69:1758–67.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Doweck I, Kaplan-Cohen V, Naroditsky I, et al. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia (New York, NY). 2006;8:1055.CrossRefGoogle Scholar
  24. 24.
    Purushothaman A, Chen L, Yang Y, et al. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem. 2008;283:32628–36.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Dabei Tang
    • 1
  • Ying Piao
    • 1
  • Shu Zhao
    • 1
  • Xudong Mu
    • 1
  • Shuo Li
    • 1
  • Wenjie Ma
    • 1
  • Ying Song
    • 1
  • Jingxuan Wang
    • 1
  • Wenhui Zhao
    • 1
    Email author
  • Qingyuan Zhang
    • 1
    • 2
    Email author
  1. 1.Department of Medical OncologyThe Tumor Hospital of Harbin Medical UniversityHarbinChina
  2. 2.Oncobiology Key Lab of Heilongjiang Common Institution of Higher LearningHarbinChina

Personalised recommendations